Prospective, randomized, multi-center, double-blind, controlled, two-period, two-treatment, crossover, adaptive enrichment phase II trial to evaluate the safety and efficacy of PD-Protec™ in peritoneal dialysis in patients with chronic renal failure
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2017
At a glance
- Drugs Alanylglutamine (Primary) ; Glucose
- Indications Peritonitis; Renal failure
- Focus Therapeutic Use
- Sponsors Zytoprotec
- 09 Jun 2017 Results from this trial published in a Zytoprotec Media Release.
- 17 Feb 2017 Status changed from active, no longer recruiting to completed.
- 14 Nov 2016 According to a Zytoprotec media release, the last patient has completed treatment in this trial.